Alnylam Pharmaceuticals, Inc.
ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products includeā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$469.31
Price-2.66%
-$12.82
1Y
Price
Market Cap
$61.517b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+2.4%
EBITDA Margin-8.6%
Net Profit Margin+18.0%
Free Cash Flow MarginRevenue
$2.462b
+9.5%
1y CAGR+36.2%
3y CAGR+32.9%
5y CAGREarnings
-$319.089m
-14.7%
1y CAGR+27.7%
3y CAGR+12.6%
5y CAGREPS
-$2.47
-14.3%
1y CAGR+28.8%
3y CAGR+14.3%
5y CAGRBook Value
$250.591m
$4.566b
Assets$4.315b
Liabilities$1.297b
DebtDebt to Assets
28.4%
-7.6x
Debt to EBITDAFree Cash Flow
-$52.088m
-22.3%
1y CAGR-39.0%
3y CAGR-25.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company